Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197911
Max Phase: Preclinical
Molecular Formula: C20H32N8O
Molecular Weight: 400.53
Associated Items:
ID: ALA5197911
Max Phase: Preclinical
Molecular Formula: C20H32N8O
Molecular Weight: 400.53
Associated Items:
Canonical SMILES: COc1ccccc1N1CCN(CCCCCCNc2nc(N)nc(N)n2)CC1
Standard InChI: InChI=1S/C20H32N8O/c1-29-17-9-5-4-8-16(17)28-14-12-27(13-15-28)11-7-3-2-6-10-23-20-25-18(21)24-19(22)26-20/h4-5,8-9H,2-3,6-7,10-15H2,1H3,(H5,21,22,23,24,25,26)
Standard InChI Key: LXKSIEBMEPDEFX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 400.53 | Molecular Weight (Monoisotopic): 400.2699 | AlogP: 1.84 | #Rotatable Bonds: 10 |
Polar Surface Area: 118.45 | Molecular Species: BASE | HBA: 9 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.42 | CX LogP: 2.77 | CX LogD: 0.20 |
Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.51 | Np Likeness Score: -1.35 |
1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J.. (2022) Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases., 227 [PMID:34710746] [10.1016/j.ejmech.2021.113931] |
Source(1):